Other languages Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Real-time Estimate Cboe BZX Other stock markets 07:16:23 29/04/2024 pm IST			5-day change	1st Jan Change
3.005 ^USD	+2.21%		-6.67%	+26.72%

20/03	North American Morning Briefing : Markets on Hold -2-	DJ
19/03	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials	06/01
Mersana Therapeutics, Inc. Announces Business Updates	05/01
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	31/23/31
Mersana Therapeutics Names Martin Huber as Chief Executive	06/23/06
Mersana Therapeutics Announces Management Changes	06/23/06
Mersana Therapeutics, Inc. Announces Chief Executive Officer Changes	06/23/06
Mersana Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
Mersana Therapeutics Shares Plummet After Analyst Downgrades, Ovarian-Cancer Therapy Failure	28/23/28
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	27/23/27
Sector Update: Health Care	27/23/27
Mersana Therapeutics Says Trial of Ovarian Cancer Treatment Misses Primary Endpoint; Shares Plunge	27/23/27
Top Premarket Decliners	27/23/27
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization	27/23/27
BB Biotech dimezza la perdita trimestrale e dice addio a Piazza Affari	21/23/21
Top Midday Decliners	15/23/15
Mersana Therapeutics Says FDA Issues Partial Clinical Hold on Enrollment in Ovarian Cancer Drug Trials; Shares Plunge	15/23/15
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Other languages

Filters